Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)	Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Site, Neoplasms, Second Primary, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Therapy-Associated Cancer, breast cancer, breast disorder, breast neoplasm, cardiovascular disorder, heart disorder, heart failure, injury, neoplasm, radiation injury, skin disorder	Recruiting	Phase 4	2025-03-14		NCT05465031

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Medical Research Agency, Poland	33
Silesian Centre for Heart Diseases	4

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Holy Cross Cancer Centre, Cardio-Oncology Division	Kielce	Poland	1
Maria Sklodowska-Curie Institute - Oncology Centre (MSCI), Gliwice Branch	Gliwice	Poland	1
Regional Cancer Centre in Opole	Opole	Poland	1
Silesian Center for Heart Diseases	Zabrze	Poland	1